newsfilter
← Latest News
Business Wire·

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

First therapeutic candidate targets Breast Cancer, Lung Cancer and Gastric Cancer Second therapeutic candidate targets platinum-resistant Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer OS